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INTRODUCTION
Infectious myonecrosis (IMN) is a severe and
emerging shrimp disease of viral etiology that was
first described in 2003 after a severe outbreak in
northeastern Brazil that was characterized by high
mortality of cultured Litopenaeus vannamei (Poulos
et al. 2006). The etiologic agent, infectious myo -
necrosis virus (IMNV), is a non-enveloped, double-
stranded RNA (dsRNA) virus that is a member of the
Totiviridae family. IMNV was discovered in Indone-
sia in 2006 (Senapin et al. 2007) and has caused
tremendous impact on the shrimp industry in both
Brazil and Indonesia (Lightner et al. 2012). During
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ABSTRACT: Infectious myonecrosis virus (IMNV) is a significant and emerging pathogen that has
a tremendous impact on the culture of the Pacific white shrimp Litopenaeus vannamei. IMNV first
emerged in Brazil in 2002 and subsequently spread to Indonesia, causing large economic losses in
both countries. No existing therapeutic treatments or effective interventions currently exist for
IMNV. RNA interference (RNAi) is an effective technique for preventing viral disease in shrimp.
Here, we describe the efficacy of a double-stranded RNA (dsRNA) applied as an antiviral thera-
peutic following virus challenge. The antiviral molecule is an optimized dsRNA construct that tar-
gets an IMNV sequence at the 5’ end of the genome and that showed outstanding antiviral protec-
tion previously when administered prior to infection. At least 50% survival is observed with a low
dose of dsRNA administered 48 h post-infection with a lethal dose of IMNV; this degree of protec-
tion was not observed when dsRNA was administered 72 h post-infection. Additionally, adminis-
tration of the dsRNA antiviral resulted in a significant reduction of the viral load in the muscle of
shrimp that died from disease or survived until termination of the present study, as assessed by
quantitative RT-PCR. These data indicate that this optimized RNAi antiviral molecule holds prom-
ise for use as an antiviral therapeutic against IMNV.
KEY WORDS:  Infectious myonecrosis virus · IMNV · RNA interence · RNAi · Double-stranded
RNA · dsRNA · Therapeutic · Shrimp · Litopenaeus vannamei
Resale or republication not permitted without written consent of the publisher
Dis Aquat Org 105: 57–64, 2013
outbreaks of IMNV, mortality ranges from 40 to 70%
prior to harvest, and epizootics cause a dramatic
increase in feed conversion (Andrade et al. 2007). An
epidemiological survey of IMNV in Brazil found that
long growout periods and high stocking densities are
significant risk factors that precipitate epizootics
(da Silva et al. 2010). The insidious presentation of
this disease, which can manifest in a gradual loss of
animals over the duration of the growout period,
makes IMNV an excellent target for a therapeutic
agent because treatments could be initiated immedi-
ately following a diagnosis of IMNV in a pond. RNA
interference (RNAi) is one possible and promising
method to mitigate viral disease in shrimp (Robalino
et al. 2005, 2007, Krishnan et al. 2009, Shekhar & Lu
2009, Hirono et al. 2011, Bartholomay et al. 2012).
RNAi has been used to prevent shrimp disease
caused by white spot syndrome virus (WSSV) (Roba -
lino et al. 2005, Xu et al. 2007), yellowhead virus
(YHV) (Tirasophon et al. 2005, 2007, Yodmuang et al.
2006), Taura syndrome virus (TSV) (Robalino et al.
2004), Penaeus stylirostris densovirus (PstDNV) (for-
merly called infectious hypodermal and hemato -
poietic necrosis virus, IHHNV) (Ho et al. 2011), and
IMNV (Loy et al. 2012). In addition to administration
prior to viral exposure, the potential for a therapeutic
effect using RNAi has been tested against many dif-
ferent RNA viruses and DNA viruses of animals and
humans, several of which are being evaluated in
Phase 1 and 2 human clinical trials as antiviral thera-
peutics (Haasnoot et al. 2007). In shrimp, a therapeu-
tic effect has been described against WSSV (Xu et al.
2007) and YHV (Tirasophon et al. 2007) after inocu -
lation with dsRNA. Some evidence indicates that
dsRNA administration and induction of RNAi path-
ways may allow for clearance of virus in shrimp nat-
urally infected with Penaeus monodon densovirus
(PmDV) (Attasart et al. 2011).
Recently, we described a sequence-optimized anti -
viral dsRNA (dsRNA 194-475) that targets the 5’ end
of the IMNV genome and shows outstanding protec-
tion from IMNV-induced disease and mortality (Loy
et al. 2012). The objective of these experiments was
to test the therapeutic efficacy of this optimized anti -
viral during an active IMNV infection.
MATERIALS AND METHODS
SPF animal rearing
Specific pathogen-free (SPF) Litopenaeus vanna -
mei postlarvae were provided by Shrimp Improve-
ment Systems (Plantation Key, FL, USA) and reared
in a biosecure animal holding facility at Iowa State
University, Ames, IA, USA. Animals were placed in
1000 l tanks containing artificial seawater (Crystal
Sea Marine Mix) at 25 ppt salinity, an oystershell air-
lift biofilter, and an activated carbon filter. The tem-
perature was maintained at 30°C. The animals were
fed a commercial growout diet until they reached 3 to
5 g in weight.
Preparation of viral inoculum
Based on a previously described methodology
(Hasson et al. 1995), tissue macerate from infected
animals (that tested negative for other shrimp
viruses by PCR) was diluted 1:3 in TN buffer (0.02 M
Tris-HCL, 0.4 M NaCl, pH 7.4) and clarified through
3 centrifugation steps: (1) 4000 × g for 30 min, (2)
15 000 × g for 15 min, and (3) 25 000 × g for 60 min,
after each of which the supernatant was removed.
The final supernatant was diluted 1:10 in sterile 2%
NaCl and passed through a 0.2 µm filter. This stock
viral clarification was aliquoted and frozen at −80°C.
Quantitative PCR analysis of RNA extracted follow-
ing a freeze-thaw indicated 105 viral copy numbers
µl−1 were present in the stock.
Determination of challenge dose
The optimum lethal dose of IMNV that resulted in
infection and disease was tested by injection in SPF
Litopenaeus vannamei weighing 8 to 10 g as des -
cribed in detail previously (Loy et al. 2012). Briefly,
each animal was injected with 100 µl of a 1:100 dilu-
tion of viral clarification into the third abdominal seg-
ment, a lethal dose that produces 100% mortality at
18 d post-challenge (d p.c.).
Quantitative reverse-transcription PCR
Quantitative reverse-transcription PCR (qRT-PCR)
was performed using methods adapted from a previ-
ous report (Andrade et al. 2007). Briefly, RNA tem-
plate was purified from 30 mg of macerated muscle
tissue and homogenized using a QIAShedder column
(Qiagen) followed by extraction with an RNeasy
Minikit (Qiagen). RNA template was eluted from the
column into 50 µl RNase-free water and stored at
−80°C until RT-PCR was performed. For qRT-PCR,
reaction templates were thawed and boiled at 100°C
58
Loy et al.: Treatment of shrimp IMNV
for 5 min prior to reverse transcription. RNA template
(2 µl) was mixed with 5 µl of One Step RT-PCR Mas-
ter Mix (Qiagen), 1 µl Enzyme Mix, 1 µl dNTP, 0.3 µl
IMNV412F (20 µM) (3’), 0.3 µl IMNV545R (20 µM),
0.3 µl IMNVP1 (10 µM), and 15.1 µl RNase-free water
for a total reaction volume of 25 µl. This reaction was
then run in duplicate or triplicate on a BioRad CFX96
real-time PCR detection system. Re verse transcrip-
tion ran for 30 min at 48°C and 10 min at 95°C. The
thermal cycling parameters included 35 cycles of 15 s
at 95°C and 1 min at 60°C. The viral copy number
was calculated using CFX Manager Software (Bio-
Rad) using an in vitro transcribed RNA standard gen-
erated according to methods from a previous report
(Andrade et al. 2007).
dsRNA preparation
dsRNA was prepared using the Ambion Mega script
RNAi Kit following the manufacturer’s instructions.
Briefly, templates for in vitro transcription were pre-
pared by PCR amplification from template cDNA us-
ing oligonucleotide primers with flanking T7 promoter
sites (Table 1) (Loy et al. 2012). For injection into ani-
mals, dsRNA was diluted in RNase-free water to
achieve a final dose of either 0.5 or 5.0 µg of dsRNA. A
total volume of 50 µl containing the de sired amount of
dsRNA in RNAse-free water, or RNAse-free water
alone as a control, was injected into the muscle of the
third abdominal segment of 3 to 5 g SPF juveniles.
Histopathology
Moribund shrimp that were observed during the
course of the experiment were fixed in whole David-
son’s fixative (Bell & Lightner 1988) for 24 h and then
transferred to 70% EtOH prior to embedding in
paraffin. In addition, 2 surviving animals from each
tank at the termination of the experiment (20 d post-
infection) were anesthetized in an ice slurry and
fixed in Davidson’s fixative (Bell & Lightner 1988),
separated into head and tail sections, embedded in
paraffin, sectioned onto slides, stained with hema-
toxylin and eosin, and evaluated for the presence of
IMNV lesions.
Shrimp bioassays
Tanks containing 200 l of synthetic seawater and
an oystershell airlift biofilter were stocked with
10 SPF juveniles weighing 3 to 5 g that were allowed
to acclimate for 72 h. The tanks were randomized,
and 3 replicates were assigned for each treatment.
Following acclimation, shrimp were challenged by
injection in the third abdominal segment with the
known lethal dose of IMNV. Sham challenge groups
received an equivalent volume of 2% NaCl, while
negative control groups received only viral diluent.
After 48 h, 5.0 µg of in vitro-synthesized dsRNA was
inoculated into animals that had been challenged
with IMNV. The sham-injection animals received an
equivalent dose of RNase-free water, and the nega-
tive control animals were sham challenged with an
equivalent dose of sterile 2% NaCl (viral diluent).
The animals were counted daily for mortality and
assessed for clinical signs. Moribund animals that
were found were fixed for histopathology. At termi-
nation, 2 animals from each tank were fixed and sub-
mitted for histopathological examination. Dead ani-
mals were removed throughout the experimental
period and frozen at −80°C.
Dose/duration bioassay
Ten shrimp per tank were challenged with IMNV
then subjected to dsRNA treatment at 24, 48, or 72 h.
Sham challenge (strict negative) groups received an
equivalent volume of 2% NaCl (viral diluent). The
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Oligonucleotide Sequence 5’-3’ Source
IMNV194T7F TAA TAC GAC TCA CTA TAG GGA AAC CGG AGC TGA CCA CAT TCC AA Loy et al. (2012)
IMNV275T7R TAA TAC GAC TCA CTA TAG GGA CTG TGT CAC ATG TTG CTG CTT CG Loy et al. (2012)
eGFPT7F TAA TAC GAC TCA CTA TAG GGA GAA TGG TGA GCA AGG GCG AGG AGC TGT Loy et al. (2012)
eGFPT7R TAA TAC GAC TCA CTA TAG GGA GAT TAC TTG TAC AGC TCG TCC ATG CCG Loy et al. (2012)
IMNV412F GGA CCT ATC ATA CAT AGC GTT TGCA Andrade et al. (2007)
IMNV545R AAC CCA TAT CTA TTG TCG CTG GAT Andrade et al. (2007)
IMNVP1 (6FAM) CCA CCT TTA CTT TCA ATA CTA CAT CAT CCC CGG (TAMRA) Andrade et al. (2007)
Table 1. Oligonucleotide primer sequences for double-stranded RNA (dsRNA) synthesis (with T7 sites underlined) and quanti-
tative RT-PCR (qRT-PCR) (IMNV412F, IMNV545R and IMNVP1)
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treatment groups were subjected to injection with
either 0.5 or 5.0 µg of in vitro-synthesized dsRNA
194-475, and the control groups consisted of animals
injected either with 5.0 µg of enhanced green fluo-
rescent protein (eGFP) dsRNA (dseGFP) or an equi -
valent volume of RNase-free water.
Statistical analysis
End-point analysis of mean survival was conducted
using 1-way ANOVA followed by a Tukey’s multiple
comparison test using JMP 8 software (SAS Institute).
Mean log viral copy-number data were normalized
from assays run in triplicate and then compared
using 1-way ANOVA followed by a Tukey’s multiple
comparison test using JMP 8 software (SAS Institute).
RESULTS
A disease-challenge model was established that
uses intramuscular injection of a clarified virus
preparation that in previous studies resulted in 100%
mortality over a 18 d period in 8 to 10 g SPF shrimp;
this was used as the virus challenge dose for all sub-
sequent experiments (Loy et al. 2012). In the first
experiment, 3 to 5 g SPF Litopenaeus vannamei were
subjected to a lethal intramuscular challenge of
IMNV. After 48 h, a single 5.0 µg dose of dsRNA194-
275 was administered to IMNV-infected animals.
The animals that were given dsRNA194-275 dsRNA
at 48 h p.c. demonstrated 50% mean survival at the
termination of the study. By comparison, animals that
received the same dose of dseGFP or the equivalent
volume of RNase-free water at 48 h p.c. showed
100% mortality (Fig. 1). Significant differences (p =
0.007) were evident between the experimental and
control groups.
Virus replication was measured from these animals
as virus genome copy number using qRT-PCR on
muscle tissues sampled from animals that were found
dead either at 8 to 12 d p.c. or at the termination of
the study. A significant reduction in virus copy num-
ber was evident between animals to which 5.0 µg
dsRNA194-275 was administered (p < 0.001) (mean
5.84 × 105 and 4.87 × 104 IMNV copy numbers µl−1
RNA in animals that either succumbed to disease or
survived until termination, respectively) compared
with animals that received a 5.0 µg dose of dseGFP or
RNAse-free water (5.43 × 106 and 4.29 × 107 IMNV
copy numbers µl−1 RNA, respectively) (Fig. 1).
Dosage and temporal effects
To further characterize the observed therapeutic
response, the temporal effects and dose-response
factors that influence a successful IMNV therapeutic
treatment were tested in a second experiment. At
24 h post-viral challenge, shrimp that received a
5.0 µg dose of dsRNA demonstrated 60% survival
after treatment compared to 50% survival of the ani-
mals treated with 0.5 µg dsRNA. Control animals that
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Fig. 1. Litopenaeus vannamei. (A) Evidence of therapeutic disease protection from an antiviral double-stranded RNA (dsRNA).
Percent survivorship of shrimp (y-axis) over time (x-axis) that were infected with a lethal dose of infectious myonecrosis virus
(IMNV) (Day 0), then injected with dsRNA194-275 at 48 h post-challenge (p.c.). Animals were observed for 20 d. n = 30 ind. in
3 replicate tanks of 10 ind. per treatment. (B) Log virus-genome copy number, as determined by quantitative RT-PCR and
based on an RNA standard curve, in muscle tissue from IMNV-infected L. vannamei that were subjected to dsRNA 194-275,
dsRNA eGFP, or sham inoculation. Muscle samples were collected from dead or moribund animals from Day 9 to 14 p.c. from
the dsRNA 194-275 mortalities, sham, and dseGFP groups. Tissues were collected from dsRNA194-275 survivors (Survivors) 
that were sacrificed at Day 20 p.c. Bars represent standard error within the sample. n = 6 ind. per group
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received 5.0 µg dseGFP demonstrated 30% survival,
and RNase-free water-injected animals showed 0%
survival (Fig. 2). Animals treated 48 h p.c. demon-
strated 90% survival in the high-dose treatment
group and 50% survival in the low-dose group, with
0% survival in groups receiving dseGFP and 20%
survival in the RNase-free water-injected group
(Fig. 2). At 72 h p.c., all experimental and control
groups showed 0% survival (Fig. 2).
Gross lesions
Shrimp in each treatment group were examined for
gross lesions daily. Presence of gross lesions was evi-
dent as single or multiple foci of opacity within the
tail muscle. All individuals in all challenged groups
developed focal or multi-focal muscle tissue opacity
by Day 5 p.c. Several individuals treated with
dsRNA194-275 in the 48 h p.c. had muscle tail opac-
ity resolve by 12 d p.c. (Fig. 3). Lesions in untreated
animals, regardless of time point, did not resolve, and
these animals succumbed to death.
Histopathology
Acute histopathologic lesions were seen only in
infected shrimp and were characterized by coagula-
tive necrosis and fragmentation of muscle bundles
with edema prominent within and between affected
muscle bundles. Infiltration of hemocytes was mostly
limited to small clusters scattered along the connec-
tive tissue septa that separate groups of muscles.
Chronic lesions were characterized by partial or total
loss of myofibers with condensation/contraction of
the fibrous connective tissue components. These
lesions correspond with characteristic histopatholog-
ical changes typically seen with IMNV infection
(Poulos et al. 2006, Loy et al. 2012).
Moribund shrimp that were found in tanks over the
course of the study were sampled from RNase-free
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Fig. 2. Litopenaeus vannamei. Effects of dose and timing on infectious myonecrosis virus (IMNV) treatment using an antiviral
double-stranded RNA (dsRNA). Survival (displayed as percentage [y-axis] over time [x-axis]) of shrimp challenged by injec-
tion with IMNV and treated with dsRNA 194-275 at (A) 24 h post-challenge (p.c.), (B) 48 h p.c., and (C) 72 h p.c. Sham animals
received an equivalent dose of RNase-free water, and negative-control animals were sham challenged with an equivalent 
dose of sterile 2% NaCl. n = 10 ind. per treatment
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water-injected controls (7 animals), eGFP dsRNA
controls (3 animals), and animals treated with
dsRNA194-275 (4 animals). Additionally, 2 animals
from each tank were sampled from the surviving ani-
mals at the termination of the study (9 animals).
Histopathological lesions in moribund animals of the
animals from all groups were characterized predom-
inantly by extensive fibrosis, occasionally with con-
current acute coagulative necrosis. Animals treated
with dsRNA194-275 that survived until termination
of the present study had chronic resolving lesions
that varied from extensive fibrosis (2 animals) to scat-
tered small foci of fibrosis (3 animals) or no signifi-
cant lesions present (3 animals). No acute lesions
were seen in any of these surviving treated animals.
DISCUSSION
These studies describe the first use of RNAi to treat
disease in shrimp with an active IMNV infection. A
previous report from our lab demonstrated that a
specific dsRNA (dsRNA194-275) confers robust and
long-term resistance to IMNV-induced disease and
mortality when administered prior to virus infection
(Loy et al. 2012). The present experiments demon-
strate that the same dsRNA can also be used to ther-
apeutically treat animals with pre-existing viral
infections. This represents a significant step toward
developing an antiviral therapeutic for infected ani-
mals as part of a disease-control program. Such a
protocol could help to eliminate or reduce IMNV
virus loads and disease burdens in infected ponds.
To determine threshold therapeutic doses of
dsRNA and simultaneously characterize the temporal
activity of the RNAi response, shrimp were subjected
to 2 doses of dsRNA (0.5 or 5.0 µg). Survival was
increased, compared to the controls, at either dose
when the animals were treated with dsRNA194-275
at 48 h post-IMNV infection. Therefore, low doses of
this antiviral dsRNA provide protection in animals
when administered early in the disease process. This
holds true when the dsRNA is delivered prior to
infection as a preventative; even a dose of 20 ng pro-
tected animals from succumbing to IMNV disease
(Loy et al. 2012). In contrast, in a therapeutic context,
when dsRNA194-275 was administered 72 h post-
challenge, no survival-enhancing effect was ob ser -
ved. This may be due to a significant amount of viral
replication taking place between 48 and 72 h, such
that the amount of virus replication that has occurred
exceeds the capacity of an RNAi antiviral effect. Pre-
vious studies of the potential therapeutic effect of
dsRNA on YHV or PstDNV disease revealed such an
effect only with higher doses and shorter intervals
between exposure and treatment. For example, a
25.0 µg dose of dsRNA provided protection 3 or 12 h
after YHV infection (Tirasophon et al. 2007), and a
5.0 to 12.5 µg dose of dsRNA was protective 24 h
post-PstDNV infection (Ho et al. 2011). No experi-
mental studies have examined the replication
dynamics of IMNV in shrimp, but the data presented
here suggest that a large amount of virus replication
occurs between 48 and 72 h post-infection, after
which time the survival-enhancing effect of dsRNA
treatment is reduced.
The temporal threshold of the efficacy of
dsRNA194-275 here may also be explained by the
target of this dsRNA, a putative cleavage protein
product called ‘Protein 1’ that contains a dsRNA-
binding motif (Poulos et al. 2006). This protein may
be involved in suppression of host cellular RNAi
responses or innate immunity during early virus
replication. Administration of dsRNA-targeting Pro-
tein 1 induces highly significant protection with low
doses, and thus, it is proposed that this protein plays
a critical role in pathogenesis. Proteins from insect
viruses such as Drosophila C virus (DCV) and Flock
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Fig. 3. Representative images of gross lesions from an individual shrimp abdomen. (A) Focal to multifocal muscle opacities were 
observed 4 d post-challenge (p.c.) (2 d post-dsRNA194-275 administration). (B) Gross lesions resolved by 12 d p.c. (10 d post-
dsRNA administration)
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House virus (FHV) have shown dsRNA-binding
activity and inhibition of the host antiviral RNAi
machinery (Li et al. 2002, van Rij et al. 2006). If this
putative dsRNA-binding protein indeed suppresses
an element of the RNAi pathway and the protein
was expressed to a high degree in a large number
of infected cells, the ability for the host to elicit an
appropriate antiviral RNAi response would be
impeded. Further studies of the role of this dsRNA-
binding protein and the role it may play in
immune suppression and in IMNV pathogenesis are
warranted.
We observed a significant therapeutic effect in
Litopenaeus vannamei from an optimized IMNV-
specific dsRNA provided within 48 h of exposure to a
lethal dose of virus. Furthermore, a small dose
(0.5 µg) of this antiviral dsRNA prevented mortality
in animals with an active, early stage infection with
IMNV. RT-PCR diagnostic methods are available and
currently being implemented on many farm labo -
ratories or pond sites to enable rapid turnaround for
a definitive diagnosis (Andrade & Lightner 2009,
Puthawibool et al. 2009). If feasible delivery methods
for dsRNA in shrimp ponds become available, a
 therapeutic treatment of this antiviral could mitigate
of IMN disease losses in virus-infected animals.
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